Message from the Cancer Institute Chair

Our Cancer Care Lives Here Through Collaboration



This year, the Premier Health Oncology Institute focused their passionate efforts on enhancing care, collaboration, and navigation for our patients close to home. Patients, such as Joanne and Dena who are highlighted in this report, remain at the center of our mission, and continue to inspire us to set and exceed our goals.

MD Anderson Cancer Network[®], a program of MD Anderson Cancer Center, is a network of select hospitals and health care systems dedicated to advancing MD Anderson Cancer Center's mission of eliminating cancer and elevating the quality and accessibility of cancer care in local communities around the world. Premier Health has access to a superior level of expertise through a collaborative team approach, and our certified physicians routinely discuss challenging cases with MD Anderson cancer experts through physician-to-physician consultations. Our care team also has access to MD Anderson treatment protocols, education, research, and more. This affiliation is just one example of our commitment to offer best-in-class care for our patients close to home.

In August, MD Anderson advised Premier Health that all of our certified medical oncologists have continuously achieved greater than 90 percent concordance to guidelines in the medical oncology peer review process. Through MD Anderson's rigorous peer review concordance process, 54 various cancer specialists have been certified through the program.

Premier Health continues to build a strong integrated network of cancer specialists, including medical, surgical, and radiation oncologists. Through our physician leadership, patients have enhanced access to new programs and services close to home such as this region's first Comprehensive Head and Neck Cancer Program, Brain Tumor Center, Liver Cancer Center, High Risk Breast Center, Gynecological Oncology Center, and Advanced Prostate Cancer Center. Premier Health strives to bring lifesaving techniques and technology to those in Southwest Ohio who cannot make it to our clinics and hospitals through the Premier Community Health and Fidelity Health Care mobile clinic, and a mobile mammography coach operated by Atrium Medical Center.

Other advancements offered are in the areas of immunotherapies, genetic counseling and testing, radiation oncology, and clinical trials. Oncology nurse navigators are one of the most important services we offer to assist patients through their cancer journey. In 2019, we expanded the number of oncology nurse navigators, who serve as a direct connection between patients, physicians, and other cancer support and survivorship resources. New technology and tools have been recently implemented, giving our nurse navigators more time to dedicate to our patients.

Another key initiative undertaken this past year was expanding supportive integrative therapies at all Premier Health cancer centers. These holistic therapies are designed to promote well-being and improve quality of life for our patients by alleviating some of the cancer treatment side effects. Therapies offered include massage, yoga, tai chi, specialized exercise classes, support groups, lymphedema therapy, therapeutic art, nutrition and cooking classes. As we look to the year ahead, cancer education, prevention, detection, and navigation will continue to be major focus areas. The Premier Health Oncology Institute's goal is to strengthen our proactive approach to care and foster a seamless patient experience that improves timely access to cancer care and survivorship.

We are entrusted to care for you, our friends and neighbors. Our cancer care team is committed to walking hand-in-hand with you and your family through this journey by providing compassionate care and hope, right here, close to home.

Charles L. Bane, MD Chair, Cancer Institute

Premier Health - Cancer Report to the Community 2019 2018 Statistical Review

Cancer Institute Physicians

Charles Bane, MD – Chair James Ouellette, DO – Vice Chair Praveena Cheruvu, MD Matthew Garrett, MD Melissa Grilliot, MD Michael Guy, MD Thomas Heck, MD Rajkamal Jit, MD Sameep Kadakia, MD Abi Katz, DO Shannon Kauffman, MD Stewart Lowry, MD Nkeiru Okoye, MD Chirag Patel, MD Ania Pollack, MD Jose Rodriguez, MD Melissa Roelle, MD Barbara Steel, MD Ryan Steinmetz, MD Erik Weise, MD

Accomplishments and Activities

The Premier Health Cancer Institute continues to provide integrated, multidisciplinary care by strengthening its comprehensive, system-wide approach to care. This is accomplished through the collaborative efforts of its cancer programs at Miami Valley Hospital, Good Samaritan Hospital (closed as of July 2018), Atrium Medical Center and Upper Valley Medical Center.

Certified Member of MD Anderson Cancer Network®

In summer 2019, MD Anderson Quality team members conducted the annual Site Safety surveys of both Premier Health and Dayton Physicians locations. The first visit focused on our Radiation Therapy facilities and quality processes in place; the second visit focused on ensuring our chemotherapy infusion areas and our pharmacies comply with the high standard of care expected of MD Anderson certified members. Through these visits, our teams had the opportunity to share the current practices in place to provide safe, comprehensive care to our cancer patients. MD Anderson team members provided positive feedback and shared additional suggestions to help us continue providing high-quality services.

Oncology Nurse Navigator Enhancements

This year we implemented new software technology for both our oncology nurse navigators and cancer registrars. One of the challenges our nurse navigators face every day is managing their reporting, so they can dedicate more time and energy to patients in their time of need. The use of oncology navigation software provides the necessary data to both illustrate the effectiveness of our navigation program and support the documentation needs of our nurse navigators. Sharing the same software and database with our cancer registry reduces duplication of work for case finding and entering treatment data between both teams. The new software has a patient-centric design, eliminating duplicative abstracting; it also provides interface capability with our current electronic medical record.

Premier Health also enhanced the oncology nurse navigator role and workflows by not only expanding the number of oncology nurse navigators but, redesigning the processes to help connect nurse navigators to our patients much sooner across all our cancer centers. These changes were identified and made to better meet the needs of our patients and to develop a close relationship throughout the patient's cancer journey.

Cancer Clinical Trials:

Cancer Clinical Trials at Premier Health supports those seeking additional treatment options through clinical trials. It is anticipated that current research trial participation leads to future disease prevention strategies and medical treatments. These trials also advance evidence-based health care. In coordination with research investigators throughout the system, our staff at the Clinical Research Center is committed to meeting the highest ethical standard of excellence in conducting clinical research and supporting quality patient care. In addition to Gynecological

Oncology Group Foundation and cooperative group trials such as "S1415CD Implementation of a Prospective Financial Impact Assessment Tool", Premier Health offers pharmaceutical, commercial, and investigator-initiated studies, such as "InformCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia". With over 40 studies available, clinical trials at Premier Health include all phases and types including prevention and control, cancer treatment, and advanced imaging studies.

New Linear Accelerator Technology:

Radiation Oncology Services – a joint venture of Dayton Physicians Network, Premier Health, and Wayne HealthCare – is advancing treatment with the arrival of new tumor-fighting medical linear accelerators at Atrium Medical Center and Upper Valley Medical Center. Linear accelerators produce a range of very high energy radiation beams that are directed to deliver radiation dose to the tumor inside the body. Premier Health's new linear accelerators will feature high resolution CT imaging, robotics, and rapid dose delivery, which delivers radiation treatment more efficiently and reduces side effects in patients. For patients, this means more accurate treatments and can mean a decrease in treatment time.

Community Partnerships

The Premier Health Cancer Institute continues to have a strong focus on community partnerships across our service area to support community education and supportive services for those in our community who have been affected by cancer. Premier Health once again worked with 10th grade students at the Dayton Regional STEM School to create cancer PSAs which were featured on social media. Premier Health continued our relationship with the American Cancer Society, fielding teams for and fundraising for local Relay for Life events and Making Strides Against Breast Cancer. Premier Health also continued to support Pink Ribbon Girls' support services for patients with breast and gynecologic cancers through the Paint the Town Pink 5K in Troy and pink fire truck visits at all Premier Health facilities.

Community Outreach

Premier Health promoted early detection of cancer through a number of screening and educational programs throughout the year. We offered free skin cancer screenings this spring in conjunction with Wright State University and Dayton Children's. Four Brake for Breakfast events in October touted the importance of mammography, followed by Shine A Light on Lung Cancer in November which brought awareness to lung cancer and recognized the patients and caregivers touched by this disease. A CME event for healthcare professionals focusing on lung cancer took place in August and featured presentations by Premier Health specialists and a specialist from MD Anderson Cancer Center and was attended by more than 30 physicians from across Southwest Ohio. Premier Health continues to administer the regional grant for the Breast and Cervical Cancer Program (BCC), which provides increased access to mammography and Pap tests for some of the most vulnerable women in the region. This year, we also upgraded our mobile mammography coach, which provides a convenient option to ensure that the women of Southwest Ohio have access to mammograms. Premier Health also hosted three Women Wisdom Wellness events focusing on breast health that were attended by over 500 women.

Hospital Cancer Committee Initiatives:

UVMC

• Provided free prostate cancer screenings to the community in tandem with the local urology office. During this two-day screening event, participants had their blood drawn on day 1 and then met with the urology team on day 2. A PSA was drawn on all participants and those at a higher risk for bladder cancer also had a urine specimen collected. During day 2, these results were discussed with the participants and an assessment of symptoms was completed. Education regarding prostate cancer was also provided during this time. Thirty-two community members participated.

AMC

• Exceeded the 50 percent requirement for the number of eligible patients who have received survivorship care planning.

Miami Valley Hospital

• Educated more than 5,900 individuals through community outreach such as cancer support groups, educational events, and health fairs. Education was identified as an area of focus in the Premier Health Oncology Community Needs Assessment, along with wellness/prevention and healthy food/nutrition to support those living with cancer.

Multiple locations:

- Implemented systemwide monthly Head and Neck Cancer conferences to bring together a multidisciplinary group of specialists to discuss complex head and neck cancer cases.
- Implemented additional integrative therapy programs for patients including exercise and massage therapy. These therapies can have a number of positive benefits for patients undergoing cancer treatment.
- Standardized systemwide pregnancy screening for women of childbearing age (ages 8-55) preparing to undergo oncology treatment. Fifty-one percent of our oncology patients are female.
- Implemented a Breast Imaging Nurse Navigator (BINN) program. The BINNs contact patients after the patient has an abnormal mammogram, and prior to their biopsy. During this navigation visit the BINN discusses the biopsy process to help alleviate anxiety and provide education. The BINN also coordinates care and conducts the appropriate follow-up. This has also been implemented at Miami Valley Hospital, Miami Valley Hospital South, and Atrium Medical Center.

Dena's Story

Dena Austin moved to Middletown from Las Vegas in September 2017, in the hope of starting a new life with her high school sweetheart.

During the previous six years, Dena lost her husband, Brent, and their 14-year-old son, Bo. After those tragic losses, she experienced what she calls a miracle – falling in love again with the high school boyfriend she hadn't seen in 25 years.

"I was looking forward to starting a new chapter," she says.

But a mere two months after her move, Dena noticed a suspicious flattening of her right breast during a self-examination in the mirror. She was diagnosed with Stage 2 breast cancer at the Women's Center at Atrium Medical Center.

Only one question consumed her: How could she break the news to her daughter, Taylor?

"I can't tell this wonderful girl, who has lost her father and her brother, yet has always persevered, that her mother has cancer," Dena told herself.

Dena's son Bo had been born four months' premature in 1997, and he never advanced beyond the developmental age of 1. "He was the joy of our lives," Dena says. "He taught us unconditional love and determination."

Bo died in 2011 at the age of 14, living far longer than doctors anticipated. Eighteen months later, Brent, a corrections officer with the Las Vegas police department, died from a heart attack.

Dena turned to Phyllis Rudokas, her oncology nurse navigator at Atrium Medical Center, for advice about how to tell her daughter.

"It is important to be honest with her and to tell her how you are feeling," Phyllis suggested. "She is a smart girl. Focus on the facts. Tell her, 'They are treating me to cure.'"

Recalls Dena, "Phyllis listened to me, and she had the exact right words to tell my daughter."

It's one of the many times Dena leaned on her oncology nurse navigator, a specially trained nurse who guides patients through all stages of cancer care. Oncology nurse navigators are experts in the best practices in cancer care who follow a multidisciplinary approach to fighting cancer. They also educate patients and family members on disease processes and treatments.

Phyllis meets patients before diagnosis, typically at the time of the biopsy. "Stress is already so high for these patients," she says. "I streamline the process so we can get them to a physician and develop a plan as soon as possible."

Phyllis schedules appointments with physicians, sometimes accompanying the patient if family members aren't available. "You need that second set of ears," she says. The oncology nurse navigator also provides patients with educational materials and connects them with community resources.

"I am my patients' advocate through all of their treatment," Phyllis says. "Patients need different things at different times. Dena already had been through a lot, so sometimes she would come by my office and just sit and talk. I have big shoulders."

Premier Health - Cancer Report to the Community 2019 2018 Statistical Review

Phyllis threw a lifeline to Dena during a time of crisis when she was far away from most of her family and friends. She had moved to Middletown to be closer to her boyfriend, Joe Stugmyer, as well as her daughter, who was attending Kentucky Christian University on a softball scholarship.

"Phyllis was fantastic," Dena says. "From the moment of diagnosis, she explained everything she could do for me. She explained that I would be very familiar with everyone on my cancer recovery team."

Phyllis promised her, "We are all fighting to cure you."

Dena's surgeon, Heather Adkins, MD, and medical oncologist, Radhika Rajsheker, MD, supported her decision to conserve her breasts. An initial four treatments of chemotherapy were followed by a lumpectomy in June 2018. After surgery, Dena endured 12 more rounds of chemotherapy and 36 rounds of radiation.

"I have never seen a more positive patient, in spite of everything Dena had gone through in losing her husband and son," Phyllis says.

The arduous treatments proved well worth it when post-treatment testing showed no evidence of disease.

Today Dena is working again, providing senior home care. "I love it; I am a caregiver at heart," she says. "I am feeding my soul and starting to feel better."

She also is looking forward to spending more time with Joe, who provided tremendous support throughout her treatment.

"God didn't put Joe and me back together after 25 years for this to be the end of our story," she says.

Enhancements in Specialized Cancer Care

The Premier Health Cancer Institute made great progress in 2019 by continuing to enhance a strong integrated network of specialized providers who mobilize to bring patients convenient, effective, and personalized cancer care. This collaborative care is provided by experts demonstrating high-quality care and sensitivity to every patient's need.

Liver:

Premier Surgical Oncology's Liver Cancer Center of Ohio brings together multiple specialists, teaming up to tackle each patient's cancer. The center's multidisciplinary approach with surgical and interventional oncology makes it the only program in Ohio – and one of only a few in the country – to combat liver cancer in this way. Patients are provided with coordinated, collaborative, and comprehensive care at the all in one center. Physicians specialize in a variety of surgical and interventional procedures by demonstrating extensive experience and using advanced medical tools and facilities.

Head and Neck:

Premier Health strives to keep patients close to home rather than traveling to large academic medical centers. The newly formed Head and Neck Cancer Program, the first in the region, provides a full spectrum of collaborative specialties including, oncologic ablation, facial reconstruction, chemoradiation, and all the intervening supportive services. This skilled and highly coordinated program offers patients diagnosis, treatment, and support services close to home. The program provides advanced care and treatment options with an interdisciplinary approach that collaborates across the full care continuum, inclusive of supportive services.

Brain and Spinal Cord Tumors:

The comprehensive neuro-oncology multispecialty team has access to the very latest research and innovative technology, to provide optimal care for brain and spinal cord tumors. With access to brain mapping at the first Brain Mapping Center in the Midwest, Premier Health's neurosurgeons have information for a highly individualized plan prior to surgery. This provides for greater precision and a delicate surgical approach, which strives to ensure vital areas of the brain are not compromised. With mapping, the physician can predict with accuracy the longterm outcomes for patients with brain tumors. The neuro-oncology team also uses an advanced medical linear accelerator, TrueBeam® Radiotherapy System. The radiotherapy system treats cancer anywhere in the body where radiation treatment is indicated, including the head and neck. It is fully integrated for image-guided radiotherapy and radiosurgery with enhanced speed and accuracy.

High Risk Breast:

The High Risk Breast Cancer Centers at Miami Valley Hospital North and Miami Valley Hospital South combine advanced technology with expert clinical assessment for earlier detection of

breast cancer in high risk women. The centers offer risk assessment, genetic counseling by a licensed certified genetic counselor, education on breast screenings and self-breast examinations, and long-term follow-up care. The staff of the High-Risk Breast Cancer Centers include a licensed certified genetic counselor, oncology nurse navigators, board-certified breast surgeons, and diagnostic radiologists. The team works cooperatively with a patient's physician and health care team.

Prostate Cancer:

Prostate Cancer is the most common cancer diagnosed in men. Patients have access to an Advanced Prostate Cancer Center located at Miami Valley Hospital South which offers advanced technology and procedures to successfully treat prostate cancer. Miami Valley Hospital also offers the UroNav Fusion Biopsy System. This technology fuses pre-biopsy magnetic resonance images of the prostate with ultrasound-guided biopsy images in real time. This provides exceptional delineation of the prostate and suspicious lesions, as well as clear visualization of the biopsy needle. The center is composed of Urology, Oncology, Radiation oncology, and a nurse navigator all working together to bring exceptional cancer care. A new technology called SpaceOAR was also made available for prostate patients receiving external beam radiotherapy at Atrium Medical Center and Miami Valley Hospital South. It is a one-time procedure done prior to radiotherapy that can protect the rectum from radiation exposure to reduce side effects during the radiotherapy. It disappears after the treatment is completed.

Supportive Services

Premier Health provides care that goes beyond medical treatment. This is accomplished by providing patients and their families with services to aid emotional, physical, and spiritual healing. These additional resources aim to make the patient's cancer journey more comfortable and manageable, throughout diagnosis, treatment, and beyond.

Integrated Therapies

There are many therapy programs offered by Premier Health that are specifically designed for people living with cancer. Programs include therapeutic art, hand and neck massages, warm water exercise, strength and conditioning classes, Tai Chi, yoga, and a movement program set to music for people with cancer or lymphedema. Many of these activities can help improve sleep, reduce stress, and improve a patient's overall quality of life.

Cancer Rehabilitation and Therapies

Premier Health offers oncology rehabilitation which helps patients regain strength, endurance, and mobility. Specialists support patients in maintaining their physical well-being and functional independence, overcoming fatigue, and reducing pain and discomfort by managing chemotherapy-related side effects. After a patient's cancer treatment is completed, physical and occupational therapy will focus on regaining function, improving strength and mobility, and ultimately returning to pre-diagnosis activity levels.

Financial Counselors

Patients are provided with customer service representatives and financial counselors who offer financial direction, especially if a patient is uninsured, underinsured, or had a recent financial hardship. Premier Health provides services that include helping patients create a payment plan and explore options for financial assistance.

Oncology Social Workers

Oncology social workers can connect you with counselors, financial counseling and support, legal assistance, and other resources.

In-Home Cancer Care

Premier Health's home health services can provide additional help and resources for cancer patients. Experienced nurses will focus on managing a patient's medical needs in the comforts and privacy of their own home. Nurses work closely with a patient's physician to ensure the best individualized treatment plan. In-home care also provides medications needed to reduce the impact of any cancer symptom, and social workers are available to advise patients on managing cancer-related issues.

Genetic Counseling

A cancer diagnosis often raises questions about cancer types that can be inherited. Genetic testing and counseling by genetic counselors can help determine if a patient's cancer is hereditary and if other family members are at risk of being diagnosed. The Premier Health Cancer Institute's team offers patients with knowledge, technology, and personal support through the genetic counseling process. The results from genetic testing can help physicians in developing an ongoing care plan for all involved.

Nutrition Counseling

Healthy eating is vital to a patient's recovery from cancer. Premier Health licensed clinical dietitians are specialists who help develop meal plans that fit a cancer patient's lifestyle. They also help find the best solutions to common side effects of treatment like loss of appetite, taste differences, and nausea.

Spiritual Care Services

A cancer diagnosis can test spiritual beliefs and cause stress. Pastoral care chaplains are members of the cancer health care team. Available 24 hours a day, seven days a week, they are specially trained to support cancer patients regardless of their faith. Chaplains routinely visit infusion rooms to provide spiritual care to patients and their families during treatment.

Survivorship Support

Cancer survivorship includes the physical, emotional, and day-to-day issues of the cancer journey. A Survivorship Care Plan helps to ensure the best possible follow-up care and quality of life. This includes collaborating with a physician to plan and get recommendations for future cancer screenings, prevention, and healthy living choices.

Supportive Products and Services

Cancer treatment can impact a patient's physical appearance including the body changes that come with mastectomy or lumpectomy or loss of their hair from chemotherapy. Premier Health's Expressions of Hope fitting events offer a full range of quality merchandise for women undergoing cancer treatment, including breast forms, shapers, bras, camisoles, compression garments, and other post-surgery products. In partnership with the American Cancer Society, Premier Health's Wig Boutique at Atrium Medical Center offers free wigs, hats, scarves, and turbans to anyone who has cancer.

Support Groups

Being with others who share a similar illness may provide patients with comfort and encouragement. Support groups are offered including a general Cancer Care Support Group, Sharing Our Strength breast cancer support group, Ostomy Support Group, Look Good, Feel Better...For Women, and Healthy Steps movement class for people dealing with cancer or lymphedema.

Premier Health Takes on Cancer with World's Leading Experts

Affiliation with MD Anderson Cancer Network® enters fourth year

The grapefruit-sized tumor in Joanne Dotson's abdomen displaced her liver and compressed her vena cava, a major vein that carries blood to the heart. No doubt about it, the malignant solitary fibrous mass was on a dark mission. It had to go.

James Ouellette, DO, FACS, a surgeon and certified physician with MD Anderson Cancer Network[®], a program of MD Anderson Cancer Center, at Premier Health, had seen and removed tumors this large before, but not one in this particular location. Part of the liver might have to be removed. How much? And if the tumor were attached to the vena cava, excising it cleanly would be risky and complicated, if not impossible.

"That's why I reached out to MD Anderson," said Dr. Ouellette, chief of surgery and director of the Hepatobiliary and Pancreatic Surgery Program at Miami Valley Hospital. "We always want to make the best decision possible when treating cancer."

'Houston, we have a problem'

Located in Houston, Texas, MD Anderson Cancer Center is one of the world's largest and most respected centers devoted exclusively to cancer care, research, education, and prevention.

Premier Health joined MD Anderson Cancer Network in 2016 after meeting the network's rigorous qualification criteria, which involves treating patients according to evidence-based medicine. Hospitals and health systems must share MD Anderson's patient-centered values and dedication to high-quality care. Premier Health has a long history of excellence in oncology, as well as a commitment to patient and family-centered care.

As a certified member of the network, Premier Health can consult and collaborate with the world's leading cancer experts, sharing the best practices and protocols being developed in the industry. The affiliation also provides Premier Health physicians access to consult virtually with MD Anderson's physicians in Houston, TX, with whom they can confer on care for particularly complex cases, such as Joanne Dotson's.

Together with MD Anderson, Dr. Ouellette found the direction he needed.

"We were looking for an alternative to surgery, such as radiation, chemotherapy, or something else," he said. "But in the end, we concluded there were no good options or alternative treatments. We had to go forward with surgery."

Joanne, meanwhile, had total faith in Premier Health and her physicians.

"I was never afraid, never worried," said the 71-year-old retired science teacher from Dayton Public Schools. "I knew I was in good hands — God's and Dr. Ouellette's."

A Successful Surgery

So confident was Joanne that as her Nov. 1, 2018, surgery date approached, she told Dr. Ouellette, "All you have to do is lift (the tumor) up and cut it out. I'm going to be okay."

Joanne's prediction proved essentially correct: the tumor was connected to the vena cava but not as extensively as Dr. Ouellette feared. He removed the tumor fully from the vena cava and the liver, with no cancer cells left behind.

"The most important thing I want people to know is that the goal of us at Premier Health and the goal of MD Anderson Cancer Network is to be able to get patients a higher level of care close to home" said Dr. Ouellette. "We at Premier Health have a very large and very experienced team, and now we've expanded that team through increased access to people at the forefront of cancer research. You can always improve your patient's care by finding good collaborators."

Joanne underwent 28 days of radiation treatment following surgery and remains cancer free. She credits God, Dr. Ouellette, and her close friends Hattie and Cam Few with getting her through her cancer journey.

"I feel blessed," she said from her Harrison Township home. "I know I'm blessed because I'm cancer free. I line dance, I ballroom dance, I watch football. I'm living life!"

MD Anderson Benefits

Premier Health is a certified member of MD Anderson Cancer Network[®], a program of MD Anderson Cancer Center.

Why is the Affiliation Important?

Patients will have access to nationally recognized cancer care protocols and best practices

while receiving their care close to home.

Benefits for Physicians:

- Premier Health physicians and caregivers have direct access to MD Anderson faculty through peer-to-peer consults
- Access to the pioneering evidence-based guidelines, treatment plans and best practices developed by the experts at MD Anderson
- Physicians from multiple specialties gather regularly for multidisciplinary cancer conferences to discuss recommended courses of treatment
- Treatment plans for even the most challenging forms of cancer

Benefits for Patients:

- Enhances our already high-quality clinical care
- Provides access to the expertise at the leading cancer center in the nation
- World-renowned cancer care delivered close to home
- Confidence knowing two leading teams are working toward one mission: to end cancer

Cancer Program Practice Profile Reports (CP3R) 2018

The estimated performance rates shown below provide cancer programs with an indication of the percentage of patients treated according to the recognized standards of care.

Each year more measures are added for review. You will note that not all measures show that 100 percent of patients were treated according to the standard. There are many reasons for this. There may have been health considerations to resolve before a certain treatment could begin, an emergency surgery that did not allow for the full collection of lymph nodes, or a patient may have chosen to delay treatment until after a special event.

The Commission on Cancer does not expect that programs will achieve 100 percent compliance on all measures. It is, however, each program's responsibility to review the cases that did not meet the standard and determine if there are ways to improve the likelihood that patients will receive the recommended care, or that the situations described above were avoidable.

Measures	Performance Rates 2018							
	AMC	GSH*	MVH	UVMC				
Colon	100%	85%	97%	92%				
At least 12 regional lymph nodes are removed and								
pathologically examined for resected colon cancer.								
Rectal	100%	100%	94%	100%				
Preoperative chemo and radiation are administered for								
clinical AJCC T3N0, T4N0, or Stage III; or post-operative								
chemo and radiation are administered within 180 days								
of diagnosis for clinical AJCC T1-2N0 with pathologic								
AJCC T3NO, T4NO, or stage III; or treatment is								
considered; for patients under the age of 80 receiving								
resection for rectal cancer.								
Breast	96%	96%	95%	100%				
Radiation therapy is administered within 1 year (365								
days) of diagnosis for women under age 70 receiving								
breast conserving surgery for breast cancer.	4.0.00/	1000/	1000	1000				
Cervix	100%	100%	100%	100%				
Chemotherapy administered to cervical cancer								
patients who received radiation for stages IB2-IV								
cancer (Group 1) or with positive pelvic nodes, positive								
surgical margin, and/or positive parametrium								
(Group 2)	1000/	0.20/	1000/	1000/				
Lung	100%	83%	100%	100%				
Surgery is not the first course of treatment for cN2, M0 cases.								
Gastric	100%	NA	100%	NA				
At least 15 regional lymph nodes are removed and	100%	NA	100%	NA				
pathologically examined for resected gastric cancer.								
pathologically examined for resected gastric cancer.	<u> </u>							

*Good Samaritan Hospital closed as of July 2018

Premier Health

Site Summary Table for New Cases 2018

SITE	GENDER AJCC STAGE GROUP												
JIL	Total Cases	Male	Female	0	I.	1	III	IV	None N/A	Unknown	% of Occurrence		
Head and Neck	Gubeb										occurrence		
Tongue	23	20	3	1	7	4	4	4	0	3	0.62%		
Salivary Gland	6	4	2	1	0	5	0	0	0	0	0.16%		
Floor of Mouth/Gum/Other	16	8	8	0	2	2	1	7	0	4	0.43%		
Nasopharynx	4	4	0	0	0	0	2	2	0	0	0.11%		
Tonsil	16 6	15 5	1	0	7	5	0	2	1	1	0.43%		
Oropharynx Hypopharynx	6 3	5 3	1 0	0 0	0 1	0 0	2 0	3 1	1 1	0 0	0.16% 0.08%		
	5	5	0	U	-	U	U	-	1	Ū	0.0070		
Digestive System Esophagus	40	30	10	0	1	9	18	4	1	7	1.08%		
Stomach	36	23	13	1	6	5	5	12	2	, 5	0.97%		
Small Intestine	27	14	13	0	5	1	2	1	15	3	0.73%		
Colon	183	80	103	2	37	34	40	53	8	9	4.93%		
Rectosigmoid Junction	24	13	11	2	3	5	7	7	0	0	0.65%		
Rectum	68	43	25	1	5	15	20	17	3	7	1.83%		
Anus/Anal Canal/Anorectum	13	5	8	1	0	7	4	1	0	0	0.35%		
Liver	54	42	12	0	15	9	15	7	4	4	1.45%		
Intrahepatic Bile Duct	11	7	3	0	3	0	2	3	1	2	0.30%		
Gallbladder	5	2	3	0	1	1	0	2	0	1	0.13%		
Other Biliary	24	12	12	0	3	3	3	9	2	4	0.65%		
Pancreas	106	59 3	47 1	1	17 2	20	11	44	5	8	2.86%		
Retroperitoneum Peritoneum/Omentum/Mesentery	4 1	3	1 1	0 0	2 0	0 0	2	0 0	0 0	0 0	0.11% 0.03%		
Other Digestive Organs	1 3	0 2	1	0	0	0	1 0	0	0 3	0	0.03%		
	5	2	1	U	U	U	U	0	5	U	0.00%		
Respiratory System	4	-	~	~	~	~	~	-	•	0	0.000		
Nose/Nasal Cavity/Middle Ear	1	1	0	0	0	0	0	1 7	0	0	0.03%		
Larynx Lung/Bronchus	34 532	31 271	3 261	2 1	7 97	8 39	4 98	7 222	0 43	6 29	0.92% 14.33%		
Trachea/Mediastinum/Other	552 1	1	201	0	97	39 0	98 0	0	45 1	29 0	0.03%		
										-			
Bones and Joints	0	0	0	0	0	0	0	0	0	0	0.00%		
oft Tissue Including Heart	17	11	6	0	4	1	4	0	7	1	0.46%		
Skin													
Melanoma	159	107	52	42	59	23	14	7	0	14	4.28%		
Other Non-Epithelial Skin	11	4	7	0	4	0	1	0	2	4	0.30%		
Breast	800	4	796	150	407	91	59	38	28	27	21.55%		
emale Genital System													
Cervix	31	0	31	0	15	8	2	3	0	3	0.84%		
Corpus & Uterus	133	0	133	0	94	2	11	7	8	11	3.58%		
Ovary	41	0	41	0	13	2	6	, 11	3	6	1.10%		
Vagina	8	0	8	0	2	0	2	2	0	2	0.22%		
Vulva	10	0	10	0	3	0	3	1	0	3	0.27%		
Other Female Genital Organs	5	0	5	0	0	1	2	0	1	1	0.13%		
Male Genital System													
Prostate	412	412	0	0	96	176	64	44	1	31	11.10%		
Testis	7	7	0	0	1	0	1	0	0	5	0.19%		
Penis	2	2	0	0	0	0	0	0	1	1	0.05%		
Jrinary System													
Bladder	185	145	40	10	36	34	11	12	72	10	4.98%		
Kidney/Renal Pelvis	138	80	40 58	0	89	8	19	12	2	2	4.98 <i>%</i> 3.72%		
Ureter	6	4	2	0	2	1	1	10	1	0	0.16%		
Other Urinary Organs	4	1	3	0	0	0	0	1	3	0	0.11%		
Brain and CNS													
Brain and CNS	46	25	21	0	0	0	0	0	46	0	1.24%		
Cranial Nerves/Other Nervous System	40 56	23	33	0	0	0	0	0	40 56	0	1.24%		
·	50	25	55	U	0	U	U	U	50	U	1.9170		
Endocrine Thyroid	0.2	10	(2)	0	50	10	1		4	7	2 2404		
Thyroid Other Endocrine including Thymus	82 21	19 13	63 8	0	50 0	19 0	1	1	4 21	7	2.21%		
Other Endocrine including Thymus	21	13	8	0	0	0	0	0	21	0	0.57%		
ymphoma													
Hodgkin's	15	12	3	0	1	4	3	4	2	1	0.40%		
Non-Hodgkin's	132	72	60 19	0	20	10	24	45	22	11	3.56%		
Myeloma	36	18	18	0	0	0	0	0	36	0	0.97%		
eukemia													
Acute Lymphocytic Leukemia	3	2	1	0	0	0	0	0	3	0	0.08%		
Chronic Lymphocytic Leukemia	5	3	2	0	0	0	0	0	4	0	0.13%		
Other Lymphocytic Leukemia	3	2	1	0	0	0	0	0	3	0	0.08%		
Acute Myeloid Leukemia	21	10 2	11 6	0	0	0	0	0	20	0	0.57%		
Chronic Musicid Leuler with	9	3 3	6 1	0 0	0 0	0 0	0	0 0	9 4	0 0	0.24% 0.11%		
Chronic Myeloid Leukemia Other Leukemia	4	7	T	U	U	0	0	0	4	0	0.11%		
Other Leukemia	4	-											
Other Leukemia Mesothelioma/Kaposi Sarcoma													
Other Leukemia Mesothelioma/Kaposi Sarcoma Mesothelioma	2	1	1	0	1	0	1	0	0	0	0.05%		
Other Leukemia Mesothelioma/Kaposi Sarcoma		1 0	1 0	0 0	1 0	0 0	1 0	0 0	0 0	0 0	0.05% 0.00%		
Other Leukemia Mesothelioma/Kaposi Sarcoma Mesothelioma	2	1											

Atrium Medical Center

Site Summary Table for New Cases 2018

Prior <th< th=""><th>SITE</th><th colspan="11">GENDER AJCC STAGE GROUP</th></th<>	SITE	GENDER AJCC STAGE GROUP										
Interpret <th>SILE</th> <th></th> <th></th> <th></th> <th>0</th> <th>I.</th> <th></th> <th></th> <th></th> <th></th> <th>Unknown</th> <th>% of Occurrence</th>	SILE				0	I.					Unknown	% of Occurrence
Interval<	Head and Neck											
Simple Displementation11000110001000 <td></td>												
nbordomin(Lamp(tamp)4220010100	Tongue	1	1	0	0	0	0	0	1	0	0	0.21%
Naces of the sectorName <th< td=""><td>-</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.21%</td></th<>	-	1	1	0	0	0	1	0	0	0	0	0.21%
ImageSSDD <thd< th="">DDDDD</thd<>												0.85%
Ordprednym000												
phypopinapox000 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>												
Departs fystem </td <td></td> <td>0.00%</td>												0.00%
sisplagin4400011001001000												
Storner<		4	4	0	0	0	1	2	0	0	1	0.85%
Index393939292030		4	2	2	0	1	1	1	1	0	0	0.85%
sector3211000200 <td>Small Intestine</td> <td>2</td> <td>2</td> <td>0</td> <td>0</td> <td>1</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> <td>0</td> <td>0.43%</td>	Small Intestine	2	2	0	0	1	0	0	0	1	0	0.43%
betwoeth markymal Cale of the second		39	17	22	1	8	8	10	9	0	3	8.30%
Analysic Canalysic Canadysic												0.64%
iver5500012200												
Intrappric file Doct1000001000												
Gallabder1000												
Other shirty110000100 <t< td=""><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	-											
Partors981000404011.13% 1.23% 1.23% 1.23% 1.23% 1.23% 1.23%1.13% 1.23% 1.23% 1.23% 1.23% 1.23% 1.23%1.13% 1.23% 1.23%1.13% 1.23% 1.23%1.13% 1.23% 1.23%1.13% 1.23% 1.23%1.13% 1.23% 1.23%1.13% 1.23% 1.23%1.13% 1.23%1.23% 1.23%												0.21%
Pertoneum/Omentum/Mesentery00 </td <td>•</td> <td></td> <td>1.91%</td>	•											1.91%
Respiratory System Nose, Nasai Carkity, Middle Ear 0	Retroperitoneum	1	1	0	0	1	0	0	0	0	0	0.21%
Nose/Nasal Carity/Middle Ear 0	-	0	0	0	0	0	0	0	0	0	0	0.00%
Nose,Nasal Carity,Minddle Ear 0	Respiratory System											
Lung/Bronchus9393939401272488729.79.79Traches/Medistinum/Other00 </td <td></td> <td>0</td> <td>0.00%</td>		0	0	0	0	0	0	0	0	0	0	0.00%
Taches/Mediastinum/Other 0 <td>-</td> <td>5</td> <td>5</td> <td>0</td> <td>0</td> <td>1</td> <td>1</td> <td>1</td> <td>2</td> <td>0</td> <td>0</td> <td>1.06%</td>	-	5	5	0	0	1	1	1	2	0	0	1.06%
Bones and Joints 0		93	39	54	0	12	7	24	38	7	2	19.79%
Soft Tissue Including Heart 1 0 1 0	Trachea/Mediastinum/Other	0	0	0	0	0	0	0	0	0	0	0.00%
Skin Melanoma 6 5 1 1 2 1 0 2 0 0 1.28% Breast 109 0 109 15 56 14 9 6 5 4 2.23% Breast 109 0 109 15 56 14 9 6 5 4 2.23% Female Genital System 2 0 2 0 1 1 0	Bones and Joints	0	0	0	0	0	0	0	0	0	0	0.00%
Skin Maanma 6 5 1 1 2 1 0 2 0 0 1.28% Breast 109 0 109 15 56 14 9 6 5 4 2.23% Breast 109 0 109 15 56 14 9 6 5 4 2.23% Genvik 2 0 2 0 1 1 0 <t< td=""><td>Soft Tissue Including Heart</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0.21%</td></t<>	Soft Tissue Including Heart	1	0	1	0	0	0	1	0	0	0	0.21%
Melanoma 6 5 1 1 2 1 0 2 0 0 128% Other Non-Epithelial Skin 1 0 0 1 0	-											
Other Non-Epithelial Skin10101000		6	5	1	1	2	1	0	2	0	0	1.28%
Breast 109 0 109 15 56 14 9 6 5 4 23.19% Female Genital System 2 0 2 0 1 1 0												0.21%
Fenale Genital System Cervix 2 0 2 0 1 1 0 </td <td></td> <td>109</td> <td></td> <td>109</td> <td>15</td> <td>56</td> <td>14</td> <td>9</td> <td>6</td> <td>5</td> <td>4</td> <td>23 19%</td>		109		109	15	56	14	9	6	5	4	23 19%
Cervix 2 0 2 0 1 1 0 0 0 1 0.843% Corpux & Uterus 4 0 4 0 3 0 0 0 0 1 0.84% Vagina 0		105	Ū	105	19	50	1 7	5	U	5	-	23.1370
Corpus & Uterus 4 0 3 0 0 0 0 1 0.85% Ovary 3 0	-	2	0	2	0	1	1	0	0	0	0	0 4 2 9/
Ovary3030100200000Valva101000001000<												
Vagina 0 <td>•</td> <td></td>	•											
Vulva 1 0 1 0 0 0 0 1 0 <td>-</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td>0.00%</td>	-	0	0	0	0	0	0	0	0	0		0.00%
Male Cenital System 59 59 0 0 10 22 11 8 0 8 12.55% Testis 1 1 0		1	0	1	0	0	0	0	1	0	0	0.21%
Prostate 59 59 0 0 10 22 11 8 0 8 12559 Testis 1 1 0	Other Female Genital Organs	1	0	1	0	0	0	1	0	0	0	0.21%
Testis 1 1 0 <td>Male Genital System</td> <td></td>	Male Genital System											
Penis 1 1 0 0 0 0 0 0 0 1 0.21% Urinary System 2 2 0 2 10 3 2 3 1 0 3 4.68% Kidney/Renal Pelvis 22 12 10 0 14 2 4 2 0 0 0.00 0 <td>Prostate</td> <td>59</td> <td>59</td> <td>0</td> <td>0</td> <td>10</td> <td>22</td> <td>11</td> <td>8</td> <td>0</td> <td>8</td> <td>12.55%</td>	Prostate	59	59	0	0	10	22	11	8	0	8	12.55%
Urinary System 22 20 2 10 3 2 3 1 0 3 4.68% Kidney/Renal Pelvis 22 12 10 0 14 2 4 2 0 0 4.68% Ureter 0	Testis	1	1	0	0	0	0	0	0	0	1	0.21%
Bladder 22 20 2 10 3 2 3 1 0 3 4.68% Kidney/Renal Pelvis 22 12 10 0 14 2 4 2 0 0 4.68% Ureter 0 </td <td>Penis</td> <td>1</td> <td>1</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> <td>0.21%</td>	Penis	1	1	0	0	0	0	0	0	0	1	0.21%
Kidney/Renal Pelvis 22 12 10 0 14 2 4 2 0 0 468% Ureter 0	Urinary System											
Ureter 0 <td>Bladder</td> <td>22</td> <td>20</td> <td>2</td> <td>10</td> <td>3</td> <td>2</td> <td>3</td> <td>1</td> <td>0</td> <td>3</td> <td>4.68%</td>	Bladder	22	20	2	10	3	2	3	1	0	3	4.68%
Other Urinary Organs 0	Kidney/Renal Pelvis	22	12	10	0	14	2	4	2	0	0	4.68%
Brain and CNS Brain 0												0.00%
Brain 0 <td>Other Urinary Organs</td> <td>0</td> <td>0.00%</td>	Other Urinary Organs	0	0	0	0	0	0	0	0	0	0	0.00%
Cranial Nerves/Other Nervous System 1 1 0 0 0 0 0 1 0 0.21% Endocrine Thyroid 6 2 4 0 3 1 0 0 0 2 1.28% Other Endocrine including Thymus 4 2 2 0 0 0 0 0 4 0 0.85% Lymphoma 1 1 0 1 0 0 0 1 0 0.43% Non-Hodgkin's 2 1 1 0 3 1 0 3 9 0 0.43% Myeloma 11 6 5 0 0 0 0 11 0 0.43% Chronic Lymphocytic Leukemia 1 1 0 0 0 0 1 0 0.21% Acute Lymphocytic Leukemia 2 1 1 0 0 0 0 1 0 0.21% Acute Lymphocytic Leukemia 1 0 0 0 0 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
Endocrine Thyroid 6 2 4 0 3 1 0 0 0 2 1.28% Other Endocrine including Thymus 4 2 2 0 0 0 0 4 0 0.85% Lymphoma .												0.00%
Thyroid 6 2 4 0 3 1 0 0 0 2 1.28% Other Endocrine including Thymus 4 2 2 0 0 0 0 0 4 0 0.85% Lymphoma 1 1 0 1 0 0 0 1 0 0.4 0 0.43% Non-Hodgkin's 16 5 11 0 3 1 0 3 9 0 3.40% Myeloma 11 6 5 0 0 0 0 10 0.43% Myeloma 11 6 5 0 0 0 0 10 0.43% Acute lymphocytic Leukemia 1 1 0 0 0 0 10 0.21% Chronic Lymphocytic Leukemia 1 1 0 0 0 0 1 0 0.43% Chronic Lymphocytic Leukemia 1 1 0 0 0 0 1 0 0.21% <	Cranial Nerves/Other Nervous System	1	1	0	0	0	0	0	0	1	0	0.21%
Other Endocrine including Thymus 4 2 2 0 0 0 0 4 0 0.85% Lymphoma Hodgkin's 2 1 1 0 1 0 0 0 1 0 0.3 9 0 0.43% Non-Hodgkin's 16 5 11 0 3 1 0 3 9 0 0.43% Mon-Hodgkin's 16 5 11 0 3 1 0 3 9 0 0.43% Myeloma 1 6 5 0 0 0 0 10 0.23% Leukemia 1 1 0 0 0 0 0 11 0 0.01 0 0.01 0.021% Chronic Lymphocytic Leukemia 1 1 0 0 0 0 0 0 0 0.021% Acute Lymphocytic Leukemia 1 0 0 0												
Lymphoma Image: constraint of the second secon	-											1.28%
Hodgkin's 2 1 1 0 1 0 0 1 0 0.43% Non-Hodgkin's 16 5 11 0 3 1 0 3 9 0 3.40% Myeloma 11 6 5 0 0 0 0 01 0 2.34% Leukemia 1 1 0 0 0 0 0 11 0 2.34% Leukemia 1 1 0 0 0 0 1 0 0.21% Chronic lymphocytic Leukemia 2 1 1 0 0 0 0 1 0 0.43% Other Lymphocytic Leukemia 1 1 0 0 0 0 1 0 0.21% Acute Myeloid Leukemia 1 0 1 0 0 0 0 0 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% <	Other Endocrine including Thymus	4	2	2	0	0	0	0	0	4	0	0.85%
Non-Hodgkin's 16 5 11 0 3 1 0 3 9 0 3.40% Myeloma 11 6 5 0 0 0 0 11 0 2.34% Leukemia 1 1 0 0 0 0 0 11 0 2.34% Leukemia 1 1 0 0 0 0 0 11 0 2.34% Leukemia 1 1 0 0 0 0 0 1 0 0.21% Chronic Lymphocytic Leukemia 2 1 1 0 0 0 0 0 0 0 0 0.21% Acute Myeloid Leukemia 2 1 1 0 0 0 0 0 0 0 0.21% Other Leukemia 0 0 0 0 0 0 0 0 0 0 0												
Myeloma 11 6 5 0 0 0 0 11 0 2.34% Leukemia 1 1 0 0 0 0 0 11 0 2.34% Acute lymphocytic Leukemia 1 1 0 0 0 0 0 1 0 0.21% Chronic lymphocytic Leukemia 2 1 1 0 0 0 0 0 1 0 0.21% Other lymphocytic Leukemia 2 1 1 0 0 0 0 0 1 0 0.43% Other lymphocytic Leukemia 2 1 1 0 0 0 0 1 0 0.21% Acute Myeloid Leukemia 2 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0.21% Other Leukemia 1 0 1 0 0 0 0 0 0 0 0 0 0 0<	-											0.43%
Leukemia Acute Lymphocytic Leukemia 1 1 0 0 0 0 0 1 0 0.21% Chronic Lymphocytic Leukemia 2 1 1 0 0 0 0 1 0 0.43% Other Lymphocytic Leukemia 1 1 0 0 0 0 1 0 0.43% Acute Myeloid Leukemia 2 1 1 0 0 0 0 1 0 0.21% Acute Myeloid Leukemia 2 1 1 0 0 0 0 1 0 0.21% Other Leukemia 0 0 1 0 0 0 0 1 0 0.21% Other Leukemia 0	-											
Acute Lymphocytic Leukemia 1 1 0 0 0 0 0 1 0 0.21% Chronic Lymphocytic Leukemia 2 1 1 0 0 0 0 1 0 0.43% Other Lymphocytic Leukemia 1 1 0 0 0 0 0 1 0 0.43% Acute Myeloid Leukemia 2 1 1 0 0 0 0 1 0 0.21% Acute Myeloid Leukemia 2 1 1 0 0 0 0 1 0 0.21% Chronic Myeloid Leukemia 1 0 1 0 0 0 0 0 0.21% Other Leukemia 0 0 1 0 0 0 0 0 0 0 0 0 0.21% Mesothelioma 0 <td>-</td> <td>11</td> <td>6</td> <td>5</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>11</td> <td>0</td> <td>2.34%</td>	-	11	6	5	0	0	0	0	0	11	0	2.34%
Chronic Lymphocytic Leukemia 2 1 1 0 0 0 0 1 0 0.43% Other Lymphocytic Leukemia 1 1 0 0 0 0 0 1 0 0.21% Acute Myeloid Leukemia 2 1 1 0 0 0 0 0 1 0 0.21% Chronic Myeloid Leukemia 2 1 1 0 0 0 0 1 0 0.43% Chronic Myeloid Leukemia 1 0 1 0 0 0 0 1 0 0.43% Other Leukemia 0 0 1 0 0 0 0 0 0.21% Other Leukemia 0 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>												
Other Lymphocytic Leukemia 1 1 0 0 0 0 0 1 0 0.21% Acute Myeloid Leukemia 2 1 1 0 0 0 0 1 0 0.43% Chronic Myeloid Leukemia 1 0 1 0 0 0 0 1 0 0.43% Other Leukemia 0 0 0 0 0 0 0 0 0.21% Other Leukemia 0 0 0 0 0 0 0 0.21% Other Leukemia 0 0 0 0 0 0 0 0.21% Mesothelioma/Kaposi Sarcoma 0 0 0 0 0 0 0 0 0.00% Kaposi Sarcoma 0 0 0 0 0 0 0 0 0 0.00% Miscellaneous 4 3 1 0 0 0 0 0 0 0.85%												0.21%
Acute Myeloid Leukemia 2 1 1 0 0 0 0 1 0 0.43% Chronic Myeloid Leukemia 1 0 1 0 0 0 0 0 1 0 0.21% Other Leukemia 0 0 0 0 0 0 0 0 0 0.21% Mesothelioma/Kaposi Sarcoma 0 0 0 0 0 0 0 0 0.00% Kaposi Sarcoma 0 0 0 0 0 0 0 0 0 0.00% Kaposi Sarcoma 0 0 0 0 0 0 0 0.00% Kaposi Sarcoma 0 0 0 0 0 0 0 0.00% Miscellaneous 4 3 1 0 0 0 0 1 0 0.85%												
Chronic Myeloid Leukemia 1 0 1 0 0 0 0 0 1 0 0.21% Other Leukemia 0												
Other Leukemia 0	-											
Mesothelioma/Kaposi Sarcoma 0<	-											
Mesothelioma 0 <t< td=""><td></td><td>-</td><td>Ť</td><td></td><td>Ť</td><td>Ŭ</td><td>Ĩ</td><td>1</td><td>J</td><td></td><td>-</td><td></td></t<>		-	Ť		Ť	Ŭ	Ĩ	1	J		-	
Kaposi Sarcoma 0		Ο	٥	٥	0	n	n	n	n	Ο	0	0 00%
Miscellaneous 4 3 1 0 0 0 0 1 0 0.85%												
Total: 470 223 246 28 125 73 74 88 45 29 100%												
	lotal:	470	223	246	28	125	73	74	88	45	29	100%

Good Samaritan Hospital* Site Summary Table for New Cases 2018

	GENDER AJCC STAGE GROUP										
SITE	Total	GEN Male	IDER Female	0	1	A. II				Unknown	% of
	Cases										Occurrence
Head and Neck											
Tongue	4	4	0	0	2	1	0	0	0	1	0.88%
Salivary Gland	0	0	0	0	0	0	0	0	0	0	0.00%
Floor of Mouth/Gum/Other	2 1	1	1	0 0	0 0	1 0	0	1 0	0 0	0	0.44%
Nasopharynx Tonsil	0	1 0	0 0	0	0	0	1 0	0	0	0 0	0.22% 0.00%
Oropharynx	0	0	0	0	0	0	0	0	0	0	0.00%
Hypopharynx	1	1	0	0	1	0	0	0	0	0	0.22%
Digestive System											
Esophagus	7	3	4	0	0	2	3	0	1	1	1.55%
Stomach	3	1	2	0	1	0	1	1	0	0	0.66%
Small Intestine	1	1	0	0	0	0	0	0	1	0	0.22%
Colon	20	9	11	0	7	3	4	4	1	1	4.42%
Rectosigmoid Junction	3	2	1	0	0	2	1	0	0	0	0.66%
Rectum	8 3	2 1	6 2	0 0	1 0	0 2	3 1	3 0	1 0	0	1.77%
Anus/Anal Canal/Anorectum Liver	3	3	2	0	0	2	1	0	1	0 0	0.66% 0.66%
Intrahepatic Bile Duct	1	1	0	0	0	0	1	0	0	0	0.22%
Gallbladder	2	1	1	0	1	0	0	1	0	0	0.44%
Other Biliary	1	0	1	0	0	0	0	0	1	0	0.22%
Pancreas	4	2	2	0	1	1	0	2	0	0	0.88%
Retroperitoneum	1	1	0	0	0	0	1	0	0	0	0.22%
Peritoneum/Omentum/Mesentery	0	0	0	0	0	0	0	0	0	0	0.00%
espiratory System											
Nose/Nasal Cavity/Middle Ear	0	0	0	0	0	0	0	0	0	0	0.00%
Larynx	4	3	1	0	2	0	0	2	0	0	0.88%
Lung/Bronchus	73	39	34	0	13	4	22	29	3	2	16.11%
Trachea/Mediastinum/Other	0	0	0	0	0	0	0	0	0	0	0.00%
Bones and Joints	0	0	0	0	0	0	0	0	0	0	0.00%
oft Tissue Including Heart	1	0	1	0	0	0	0	0	1	0	0.22%
ikin											
Melanoma	4	4	0	1	0	0	1	2	0	0	0.88%
Other Non-Epithelial Skin	0	0	0	0	0	0	0	0	0	0	0.00%
Breast	159	2	157	31	81	19	17	8	3	0	35.10%
Female Genital System											
Cervix	4	0	4	0	2	1	1	0	0	0	0.88%
Corpus & Uterus	8	0	8	0	7	0	1	0	0	0	1.77%
Ovary	2	0	2	0	0	0	1	0	0	1	0.44%
Vagina	2	0	2	0	1	0	0	1	0	0	0.44%
Vulva	0	0	0	0	0	0	0	0	0	0	0.00%
Other Female Genital Organs	1	0	1	0	0	1	0	0	0	0	0.22%
Male Genital System											
Prostate	57	57	0	0	14	29	8	6	0	0	12.58%
Testis	1	1	0	0	0	0	0	0	0	1	0.22%
Penis	0	0	0	0	0	0	0	0	0	0	0.00%
Urinary System											
Bladder	26	19	7	0	8	5	1	1	10	1	5.74%
Kidney/Renal Pelvis	4	1	3	0	2	0	1	1	0	0	0.88%
Ureter Other Urinary Organs	0	0 0	0	0 0	0 0	0 0	0 0	0	0 0	0	0.00%
Other Urinary Organs	1	U	1	0	0	U	0	1	0	0	0.22%
Brain and CNS	-		-	-	-	-	-	-	-	-	
Brain Granial Namos (Other Namous System	1	1	0	0	0	0	0	0	1	0	0.22%
Cranial Nerves/Other Nervous System	16	4	2	0	0	0	0	0	6	0	1.32%
Endocrine											
Thyroid	0	0	0	0	0	0	0	0	0	0	0.00%
Other Endocrine including Thymus	3	2	1	0	0	0	0	0	3	0	0.66%
ymphoma											
Hodgkin's	0	0	0	0	0	0	0	0	0	0	0.00%
Non-Hodgkin's	14	10	4	0	2	1	0	6	3	2	3.09%
Myeloma	4	1	3	0	0	0	0	0	4	0	0.88%
eukemia											
Acute Lymphocytic Leukemia	0	0	0	0	0	0	0	0	0	0	0.00%
Chronic Lymphocytic Leukemia	0	0	0	0	0	0	0	0	0	0	0.00%
Other Lymphocytic Leukemia	1	0	1	0	0	0	0	0	1	0	0.22%
Acute Myeloid Leukemia	2	1	1	0	0	0	0	0	2	0	0.44%
Chronic Myeloid Leukemia	0	0	0	0	0	0	0	0	0	0	0.00%
Other Leukemia	1	1	0	0	0	0	0	0	1	0	0.22%
Macathaliama /Kanaci Carcoma						_	•	~	0	0	0.00%
	~	-						~	0		0.00%
Mesothelioma	0	0	0	0	0	0	0	0	0	0	
Mesothelioma Kaposi Sarcoma	0	0	0	0	0	0	0	0	0	0	0.00%

-	n	а	n	сr	 1e	

*Good Samaritan Hospital closed as of July 2018

Miami Valley Hospital Site Summary Table for New Cases 2018

SITE		GEN	IDER			AJCC STAGE GROUP					
	Total Cases	Male	Female	0	I.	Ш	ш	IV	None N/A	Unknown	% of Occurrence
Lload and Nock	Cases										Occurrence
Head and Neck Tongue	13	11	2	1	5	1	2	2	0	2	0.52%
Salivary Gland	4	3	1	1	0	3	0	0	0	0	0.16%
Floor of Mouth/Gum/Other	7	4	3	0	0	1	0	3	0	3	0.28%
Nasopharynx	1	1	0	0	0	0	0	1	0	0	0.04%
Tonsil	7	7	0	0	4	2	0	1	0	0	0.28%
Oropharynx	5	4	1	0	0	0	2	2	1	0	0.20%
Hypopharynx	1	1	0	0	0	0	0	1	0	0	0.04%
Other Oral Cav & Phary	0	0	0	0	0	0	0	0	0	0	0.00%
Digestive System	27	24	ć	•	-	<i>,</i>	10	2		_	1 0000
Esophagus Stomach	27 26	21 18	6	0 1	1 4	6 3	12 3	3	0	5	1.08%
Stornach Small Intestine	26 18	18 9	8 9	0	4	5 0	5	10 1	1 12	4 2	1.04% 0.72%
Colon	105	48	57	1	17	19	21	36	7	4	4.20%
Rectosigmoid Junction	18	9	9	1	3	3	6	5	0	0	0.72%
Rectum	44	28	16	1	3	9	14	11	1	5	1.76%
Anus/Anal Canal/Anorectum	5	2	3	0	0	4	1	0	0	0	0.20%
Liver	45	34	11	0	15	7	12	5	3	3	1.80%
Intrahepatic Bile Duct	9	6	3	0	3	0	1	2	1	2	0.36%
Gallbladder	2	1	1	0	0	0	0	1	0	1	0.08%
Other Biliary	22	11	11	0	3	3	2	9	1	4	0.88%
Pancreas Retroperitoneum	88 2	47 1	41 1	1 0	14 1	14 0	11 1	36 0	5 0	7 0	3.52% 0.08%
Peritoneum/Omentum/Mesentery	2	1 0	1	0	0	0	1	0	0	0	0.08%
Other Digestive organs	3	2	1	0	0	0	0	0	3	0	0.12%
	-	-	-	-	-	J	Ţ		-	Ţ	
Respiratory System Nose/Nasal Cavity/Middle Ear	0	0	0	0	0	0	0	0	0	0	0.00%
Larynx	19	17	2	2	4	4	2	2	0	5	0.00%
Lung/Bronchus	326	165	161	1	-+ 72	4 24	47	133	33	16	13.05%
Trachea/Mediastinum/Other	1	1	0	0	0	0	0	0	1	0	0.04%
Bones and Joints	0	0	0	0	0	0	0	0	0	0	0.00%
Soft Tissue Including Heart	15	11	4	0	4	1	3	0	6	1	0.60%
Skin											
Melanoma	145	94	51	39	55	21	13	3	0	14	5.80%
Other Non-Epithelial Skin	9	3	6	0	3	0	1	0	2	3	0.36%
Breast	457	2	455	90	239	45	29	20	19	15	18.29%
Female Genital System											
Cervix	23	0	23	0	12	6	1	2	0	2	0.92%
Corpus & Uterus	112	0	112	0	78	1	10	6	8	9	4.48%
Ovary	36	0	36	0	12	2	5	9	3	5	1.44%
Vagina	6	0	6	0	1	0	2	1	0	2	0.24%
Vulva Other Female Genital Organs	8 3	0 0	8 3	0 0	3 0	0 0	3 1	0 0	0 1	2 1	0.32% 0.12%
-	5	0	5	0	U	U	Ŧ	0	T	Ŧ	0.1270
Male Genital System	270	270	•	•	65	100		20		22	10.01%
Prostate	270	270	0	0 0	65 1	109	44	28 0	1 0	23	10.81%
Testis Penis	5 1	5 1	0 0	0	0	0 0	1 0	0	0	3 0	0.20% 0.04%
	-	-	U	Ū	U	U	U	Ū	-	Ū	0.0470
Urinary System	124	04	20	0	22	22	7	0	(2)	1	4.06%
Bladder Kidney/Renal Pelvis	124 105	94 60	30 45	0 0	22 69	23 5	7 14	9 14	62 1	1 2	4.96% 4.20%
Ureter	105 6	60 4	45 2	0	69 2	5	14	14 1	1	2	4.20% 0.24%
Other Urinary Organs	3	4	2	0	0	0	0	0	3	0	0.24%
Brain and CNS		-									
Brain	42	22	20	0	0	0	0	0	42	0	1.68%
Cranial Nerves/Other Nervous System		18	20 31	0	0	0	0	0	42 49	0	1.88%
-				-	-	-	-	-		-	
Endocrine Thyroid	68	14	54	0	41	17	1	1	4	4	2.72%
Other Endocrine including Thymus	68 14	14 9	54 5	0	41 0	0	0	1 0	4 14	4 0	2.72% 0.56%
	17	5	5	0	0	0	0	U	<u>+</u> 7	J	0.5076
Lymphoma Hodgkin's	17	10	n	0	0	л	5	л	0	1	0 4004
Hodgkin's Non-Hodgkin's	12 84	10 45	2 39	0 0	0 12	4 7	3 20	4 31	0 10	1 4	0.48% 3.36%
Myeloma	84 19	45 11	8	0	0	0	20	31 0	10 19	4 0	3.36% 0.76%
-	17	11	5	5	5	5	5	U	<u>.</u> ,	J	0.7070
Leukemia	2	1	1	0	0	0	0	0	2	0	0.0004
Acute Lymphocytic Leukemia	2 3	1 2	1 1	0 0	0 0	0 0	0 0	0 0	2 3	0	0.08% 0.12%
Chronic Lymphocytic Leukemia Other Lymphocytic Leukemia	3 1	2	1	0	0	0	0	0	3 1	0 0	0.12%
Acute Myeloid Leukemia	1 17	1 8	9	0	0	0	0	0	1 17	0	0.04%
Chronic Myeloid Leukemia	8	° 3	5	0	0	0	0	0	8	0	0.88%
Other Leukemia	3	2	1	0	0	0	0	0	3	0	0.12%
Mesothelioma/Kaposi Sarcoma											/*
Mesothelioma/Kaposi Sarcoma Mesothelioma	2	1	1	0	1	0	1	0	0	0	0.08%
Kaposi Sarcoma	2	0	0	0	0	0	0	0	0	0	0.08%
Miccollanaouc											
Miscellaneous Total:	47 2498	26 1169	21 1329	0 139	0 771	0 345	0 299	0 393	47 396	0 155	1.88% 100%

Upper Valley Medical Center Site Summary Table for New Cases 2018

SITE		GENDER AJCC STAGE GROUP									
	Total Cases	Male	Female	0	I	Ш	ш	IV	None N/A	Unknown	% of Occurrenc
Head and Neck											
Tongue	5	4	1	0	0	2	2	1	0	0	1.72%
Salivary Gland	1	0	1	0	0	1	0	0	0	0	0.34%
Floor of Mouth/Gum/Other	3	1	2	0	1	0	0	2	0	0	1.03%
Nasopharynx	1	1	0	0	0	0	0	1	0	0	0.34%
Tonsil	4	3	1	0	1	1	0	0	1	1	1.37%
Oropharynx Hypopharynx	1 1	1 1	0 0	0 0	0 0	0 0	0 0	1 0	0 1	0 0	0.34% 0.34%
	-	-	Ū	U	U	U	U	U	-	Ū	0.5470
Digestive System Esophagus	2	2	0	0	0	0	1	1	0	0	0.69%
Stomach	3	2	1	0	0	1	0	0	1	1	1.03%
Small Intestine	6	2	4	0	2	1	1	0	1	1	2.06%
Colon	19	6	13	0	5	4	5	4	0	1	6.53%
Rectosigmoid Junction	0	0	0	0	0	0	0	0	0	0	0.00%
Rectum	11	8	3	0	1	4	2	2	1	1	3.78%
Anus/Anal Canal/Anorectum	4	2	2	1	0	1	1	1	0	0	1.37%
Liver	1 0	0 0	1 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0.34% 0.00%
Intrahepatic Bile Duct Gallbladder	0	0	0	0	0	0	0	0	0	0	0.00%
Other Biliary	0	0	0	0	0	0	0	0	0	0	0.00%
Pancreas	5	2	3	0	2	1	0	2	0	0	1.72%
Retroperitoneum	0	0	0	0	0	0	0	0	0	0	0.00%
Peritoneum/Omentum/Mesentery	0	0	0	0	0	0	0	0	0	0	0.00%
Respiratory System											
Nose/Nasal Cavity/Middle Ear	1	1	0	0	0	0	0	1	0	0	0.34%
Larynx	6	6	0	0	0	3	1	1	0	1	2.06%
Lung/Bronchus	40	28	12	0	0	4	5	22	0	9	13.75%
Trachea/Mediastinum/Other	0	0	0	0	0	0	0	0	0	0	0.00%
Bones and Joints	0	0	0	0	0	0	0	0	0	0	0.00%
Soft Tissue Including Heart	0	0	0	0	0	0	0	0	0	0	0.00%
Skin											
Melanoma	4	4	0	1	2	1	0	0	0	0	1.37%
Other Non-Epithelial Skin	1	1	0	0	0	0	0	0	0	1	0.34%
Breast	75	0	75	14	31	13	4	4	1	8	25.77%
	/5	0	/5	14	71	15	4	4	-	0	23.1170
Female Genital System Cervix	2	•	2	0	0	0	0	1	0	1	0.00%
Corpus & Uterus	2 9	0 0	2 9	0 0	0 6	0 1	0 0	1 1	0 0	1 1	0.69% 3.09%
Ovary	0	0	0	0	0	0	0	0	0	0	0.00%
Vagina	0	0	0	0	0	0	0	0	0	0	0.00%
Vulva	1	0	1	0	0	0	0	0	0	1	0.34%
Other Female Genital Organs	0	0	0	0	0	0	0	0	0	0	0.00%
Male Genital System											
Prostate	26	26	0	0	7	16	1	2	0	0	8.93%
Testis	0	0	0	0	0	0	0	0	0	0	0.00%
Penis	0	0	0	0	0	0	0	0	0	0	0.00%
Urinary System											
Bladder	13	12	1	0	3	4	0	1	0	5	4.47%
Kidney/Renal Pelvis	7	7	0	0	4	1	0	1	1	0	2.41%
Ureter	0	0	0	0	0	0	0	0	0	0	0.00%
Other Urinary Organs	0	0	0	0	0	0	0	0	0	0	0.00%
Brain and CNS											
Brain	3	2	1	0	0	0	0	0	3	0	1.03%
Cranial Nerves/Other Nervous System	0	0	0	0	0	0	0	0	0	0	0.00%
Endocrine											
Thyroid	8	3	5	0	6	1	0	0	0	1	2.75%
Other Endocrine including Thymus	0	0	0	0	0	0	0	0	0	0	0.00%
ymphoma											
Hodgkin's	1	1	0	0	0	0	0	0	1	0	0.34%
Non-Hodgkin's	18	12	6	0	3	1	4	5	0	5	6.19%
Myeloma	2	0	2	0	0	0	0	0	2	0	0.69%
Leukemia											
Acute Lymphocytic Leukemia	0	0	0	0	0	0	0	0	0	0	0.00%
Chronic Lymphocytic Leukemia	0	0	0	0	0	0	0	0	0	0	0.00%
Other Lymphocytic Leukemia	0	0	0	0	0	0	0	0	0	0	0.00%
Acute Myeloid Leukemia	0	0	0	0	0	0	0	0	0	0	0.00%
Chronic Myeloid Leukemia	0	0	0	0	0	0	0	0	0	0	0.00%
Other Leukemia	0	0	0	0	0	0	0	0	0	0	0.00%
Mesothelioma/Kaposi Sarcoma											
Mesothelioma	0	0	0	0	0	0	0	0	0	0	0.00%
Kaposi Sarcoma	0	0	0	0	0	0	0	0	0	0	0.00%
			2	•	0	0	0	•	7	0	2 410/
Miscellaneous	7	5	2	0	0	0	0	0	7	0	2.41%

Cancer Committees

ATRIUM MEDICAL CENTER

Ryan Steinmetz, MD, Chair Radiation Oncology

Heather Adkins, MD General Surgery

Logan Beeman, BSN, RN Manager, Medical Surgical Unit

Lisa Boster, RHIT, CTR Cancer Registry

Ravi Cherukuri, MD Radiology

Melissa Cottman, RT Director, Medical Imaging

Sandy Fletcher, BSN, RN, CNOR, OCN, CCRP Research/Clinical Trials

Nicholas Gibbs, RHIT Cancer Registry

Tina Gregory, MHA, BSN, RN Associate Chief Nursing Officer

Theresa Gustafson, BS, RT (R)(M) System Manager, Medical Imaging

Debbie Hatter, MSN, APRN, FNP-BC, OCN Manager, Compton Infusion Center/Oncology Services

Deborah Hurst, MS, APRN, ACNS Palliative Care

Sameep Kadakia, MD Head and Neck Surgery

Tia Leedy, LSW Outpatient Oncology Social Services

Jamey Phillips, RPh Pharmacy Nkeiruka Okoye, MD Medical Oncology

Alan Prok, MD Pathology

Mridula Reddy, MD Medical Oncology

Phyllis Rudokas, BS, RN, OCN, CBCN Oncology Nurse Navigator

Sharon Spruill, RN Palliative Care

John Weske, MD Radiology

Ronald Wilger, PT, DPT Therapy Manager, Rehabilitation/Lymphedema Services

Teresa Wilson, BSN, RN, OCN Oncology Nurse Navigator

Miami Valley Hospital

Mark Marinella, MD, FACP, Chair Medical Oncologist

Melissa Alcazar, APRN, FNP Palliative Care

Diane Anderson, DO Radiologist

Mark Anstadt, MD, FACS Cardiothoracic Surgery

Rebecca Balaj, MD Pathologist

Charles Bane, MD Medical Oncologist/Medical Director of Oncology Services MVHN

Patricia Braeuning, MD Interventional Radiology

Walter Burnell, BA Cancer Center Resource Coordinator

Faith Callif-Daley, LCGC Certified Genetic Counselor

Douglas Ditzel, DO Radiation Oncologist

Pam Engle, CTR Supervisor, Oncology Information Center

Sandy Evers, RN, BS, VA-BC Clinical Trials Research Nurse

Mary I. Fisher, PT, PhD, OCS, CLT Physical Therapist

Anna Frantz, MSW, LISW Oncology Social Worker

Howard Gross, MD, FACP Medical Oncologist

Michael S. Guy, MD, ABOG, FACOG Gynecologic Oncology

Nancy Hampton-Jones, DNP, APRN, AOCNS, AGCNS-BC Neurosurgery Chelsea Harris, RN, CHPN Palliative Care

Deborah Hurst, MS, RN, ACNS-BC, CHPN Palliative Care

Connie Ickes, MSW, LISW-S Oncology Social Worker

Shamim Jilani, MD, FACP Medical Oncologist

Sameep Kadakia, MD, FACS Otolaryngologist

Melissa Laux, CTR Oncology Information Center

Brenda McCracken, BS, CTR Oncology Data Specialist

Amy McKenna, BSN, RN Oncology Nurse Navigator

Elena Mikalauskas, MS, RN, OCN, AOCNS Clinical Nurse Specialist

Miranda Mougey, BS, CTR Oncology Information Center

Amanda Musser, MSN, RN Director Clinical Operations

Bobbie Newsome, BSN, RN Oncology Research Data Coordinator

Denise Nichols, MSW, LISW-S Oncology Social Workers

Deborah Niese American Cancer Society

James Ouellette, DO, FACS Surgical Oncologist

Ania Pollack, MD, FACS, FAANS Neurology

Alison Potts, MSN, RN Director of Nursing

Greg Rasp, MD Radiation Oncologist Joann Ringer President, Miami Valley Hospital South

Jose Rodriguez, MD, FACS Cardiothoracic Surgery

Melissa Roelle, MD, FACS Medical Director of High Risk Breast Center, MVHS

Julie Sawyer, MS, LCGC Certified Genetic Counselor

Carol Stadler, PharmD, RPh Clinical Pharmacist

Allen Stephens, DO Pathologist

Nancy Thoma, BSN, RN, OCN Oncology Nurse Navigator

Emily Townsend, MSN, RN, OCN Oncology Program Manager – MVH

Stacey Utt, BS, CTR Oncology Information Center

Nicki Vance, BSN, RN Oncology Education

Susan Wetzel, CTR Oncology Information Center

Burhan Yanes, MD Medical Oncologist/Medical Director MVH

Upper Valley Medical Center

Dr. Ronald Setzkorn, MD, Chair Radiation Oncology

Dr. Wincha Chong, MD Diagnostic Radiology

Dr. Joseph Ridgeway, MD Diagnostic Radiology

Dr. Jared Griffith, MD Diagnostic Radiology

Dr. Chris Rolisky, MD Pathology

Dr. Allen Stephens, MD Pathology

Dr. Zachary Simmons, MD Cancer Liaison Physician / General Surgery

Dr. Stewart Lowry, MD General Surgery

Dr. Rajeev Kulkarni, MD Medical Oncology

Sarah Jones, MS, RN, AOCNS, ACNS-BC Cancer Program Administrator / Oncology CNS Manager, QI Rep

Caitlin Conaway, MSN, RN Community Outreach Coordinator

Heather Penwell, BSN, RN Clinical Research Coodinator Charles Strawser, RN Palliative Care

Jim Dabbelt, CTR Certified Tumor Registrar

Dusti Mathes Cancer Conference Coordinator

Pam Wilson, LSW Social Worker / Psychosocial Services Coordinator

Elizabeth Morgan, MSW Social Worker

Cancer Committee Chairs

Premier Health has taken an integrated, comprehensive approach to cancer services. This brings together a collaboration of the Premier Health hospitals and the committee chairs for the hospitals.

MVH: Mark Marinella, MD, FACP - chair Medical Oncology

AMC: Ryan Steinmetz, MD, Chair Radiation Oncology

UVMC: Dr. Ronald Setzkorn, MD, Chair Radiation Oncology